Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24908451 | 1.00 | GPR84 (0.38) | GPR84FFAR1PLA2G4AMAPTLCK | |
| SCHEMBL25452753 | 1.00 | GPR84 (0.38) | GPR84FFAR1PLA2G4AMAPTLCK | |
| SCHEMBL25452696 | 1.00 | GPR84 (0.38) | GPR84FFAR1PLA2G4AMAPTLCK | |
| SCHEMBL24908530 | 0.99 | GPR84 (0.37) | GPR84FFAR1PLA2G4AMAPTLCK | |
| SCHEMBL24908432 | 0.96 | KDM4E (0.36) | GPR84FFAR1PLA2G4AMAPTLCK | |
| SCHEMBL25452623 | 0.87 | GPR84 (0.37) | GPR84FFAR1PLA2G4AMAPTLCK | |
| SCHEMBL24908550 | 0.81 | KDM4E (0.37) | PLA2G4AMAPTKDM4EALDH1A1 | |
| SCHEMBL24908455 | 0.77 | KDM4E (0.39) | KDM4E | |
| SCHEMBL20419027 | 0.76 | NR1I2 (0.36) | KDM4EALDH1A1 | |
| SCHEMBL23897196 | 0.75 | NR1I2 (0.35) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | GPR84 1094/4885FFAR1 333/4885PLA2G4A 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.